UDCA Safety Profile: Side Effects, Drug Interactions & Contraindications

Ursodeoxycholic acid (UDCA) has one of the best-documented safety profiles among hepatoprotective agents. With over three decades of post-market surveillance, more than 15,000 patients studied in controlled clinical trials, and millions of patient-years of exposure, the body of safety data is large. The data below is compiled from clinical trials, pharmacovigilance databases, and regulatory labeling for pharmaceutical buyers evaluating UDCA for formulation or procurement.

General Tolerability

UDCA is classified as generally well-tolerated across all studied populations. In the Lindor et al. (1994) trial of UDCA for primary biliary cholangitis (PBC), adverse events occurred at similar rates in the UDCA and placebo arms, with no statistically significant difference in discontinuation rates. The drug's mechanism ( replacing toxic hydrophobic bile acids from the enterohepatic circulation ) is itself cytoprotective, which contributes to its benign safety profile. A Cochrane systematic review of 16 randomized clinical trials involving 1,447 participants with PBC (Rudic et al., 2012) found no significant increase in serious adverse events with UDCA compared to placebo or no intervention.

Common Side Effects

Diarrhea (Dose-Dependent)

Diarrhea is the most frequently reported adverse event associated with UDCA, occurring in approximately 2-9% of patients depending on dose and study population. The mechanism is osmotic: unabsorbed bile acids in the colon stimulate chloride secretion and increase colonic motility. This effect is dose-dependent ( higher per-kilogram doses (above 20 mg/kg/day) correlate with increased incidence ) and typically mild to moderate in severity. In most cases, diarrhea resolves with dose reduction or resolves spontaneously within the first two weeks of treatment as the gastrointestinal tract adapts.

For pharmaceutical formulators, this side effect profile informs release kinetics: immediate-release UDCA tablets deliver a bolus of bile acid to the small intestine, while modified-release formulations (studied but less common in commercial products) can attenuate gastrointestinal effects by distributing UDCA delivery along a longer intestinal segment.

Less Common Gastrointestinal Effects

• Constipation: Reported in less than 1% of patients. The paradoxical occurrence of both diarrhea and constipation reflects inter-individual variation in bile acid transporter expression and gut microbiome composition.
• Nausea and vomiting: Reported in approximately 1-3% of patients in clinical trials. Usually mild and transient. Taking UDCA with food can reduce nausea incidence.
• Dyspepsia and upper abdominal pain: Infrequent (less than 2% incidence) and generally not considered causally related to UDCA.

Additional Reported Effects

Pruritus, urticaria, and rash have been reported rarely (less than 1% incidence). Notably, UDCA is actually used to treat pruritus associated with cholestasis ( when pruritus occurs during UDCA therapy, it is typically attributable to the underlying liver disease rather than the drug. Back pain, headache, dizziness, and fatigue appear in post-marketing surveillance reports but at rates indistinguishable from background population incidence.

Contraindications

The following conditions are listed as contraindications in UDCA prescribing information across major regulatory jurisdictions (FDA, EMA, PMDA):

Drug Interactions

Clinically Significant Interactions

Use in Special Populations

Pregnancy

UDCA is classified as Pregnancy Category B by the FDA under the legacy classification system (animal reproduction studies have failed to demonstrate a fetal risk, but no adequate and well-controlled studies exist in pregnant women). Under the current PLLR labeling format, the prescribing information notes that available data from published case reports, case series, and observational studies over several decades have not identified a UDCA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

UDCA is used off-label for intrahepatic cholestasis of pregnancy (ICP), a condition affecting approximately 0.5-1.5% of pregnancies in North America and up to 5% in certain South American populations. The largest randomized trial, the PITCHES trial (Chappell et al., 2019, The Lancet, n=605), found that UDCA did not significantly reduce adverse perinatal outcomes compared to placebo (adjusted risk ratio 0.85, 95% CI 0.62-1.15), though it confirmed the good safety profile with no increase in adverse fetal outcomes. Earlier smaller trials had suggested clinical benefit, and UDCA remains widely used in ICP management. This is the single application of UDCA with the largest body of pregnancy-specific safety evidence.

Pediatric and Geriatric Populations

UDCA is used in pediatric hepatology at weight-adjusted doses for conditions including biliary atresia (post-Kasai procedure), progressive familial intrahepatic cholestasis (PFIC), and cystic fibrosis-associated liver disease. Safety data in children is primarily from open-label studies and clinical registries, with no pediatric-specific safety signals identified beyond those seen in adults. In geriatric patients, no dose adjustment is recommended; the safety profile in patients over 65 years mirrors that of the general adult population.

Hepatic and Renal Impairment

Paradoxically, UDCA is indicated for patients with hepatic impairment (PBC, PSC), and no dose adjustment is required based on liver function alone. In decompensated cirrhosis (Child-Pugh Class C), the benefit-risk ratio shifts: UDCA should be used with caution, and higher doses (28-30 mg/kg/day) have been associated with increased adverse events in this population per the Mayo Clinic trial data. No dose adjustment is recommended for renal impairment; bile acids are primarily excreted via the biliary route, not renally.

Safety Data from Clinical Trials and Pharmacovigilance

The WHO VigiBase database (the largest global pharmacovigilance repository maintained by the Uppsala Monitoring Centre) contains adverse event reports for UDCA spanning from its first approval to the present. The most commonly reported adverse events in VigiBase align with clinical trial data: gastrointestinal disorders (diarrhea, nausea), with no novel or unexpected safety signals emerging over decades of use.

The 1997 combined analysis of the three major PBC trials (Poupon et al., Gastroenterology, n=548) and the Cochrane systematic review (Rudic et al., 2012; 16 trials, 1,447 participants) together provide the largest safety dataset for UDCA in PBC. Key safety findings include:

• Serious adverse events occurred at similar rates in UDCA and placebo groups [citation needed]
• Discontinuation due to adverse events was approximately 3% in both UDCA and placebo arms [citation needed]
• No drug-related deaths reported across the pooled trial data
• No hepatotoxicity signal ( on the contrary, UDCA reduced alkaline phosphatase, ALT, and GGT levels

Implications for Pharmaceutical Buyers and Formulators

From a procurement and quality perspective, UDCA's well-characterized safety profile reduces several categories of business risk:

• Regulatory risk: Established safety data supports regulatory filings in new markets and reduces the burden of clinical safety documentation in DMF/CEP submissions.
• Formulation risk: The absence of narrow therapeutic index characteristics, complex drug-drug interactions, or organ-specific toxicity simplifies formulation development and reduces the likelihood of safety-driven reformulation requirements.
• Supply chain risk: No safety-driven recalls or market withdrawals have occurred for UDCA API, unlike several other hepatoprotective agents that were withdrawn due to hepatotoxicity signals.

Explore Related Resources